Bee Venom and Its Peptide Component Melittin Suppress Growth and Migration of Melanoma Cells via Inhibition of PI3K/AKT/mTOR and MAPK Pathways
- PMID: 30866426
- PMCID: PMC6429308
- DOI: 10.3390/molecules24050929
Bee Venom and Its Peptide Component Melittin Suppress Growth and Migration of Melanoma Cells via Inhibition of PI3K/AKT/mTOR and MAPK Pathways
Abstract
Malignant melanoma is the deadliest form of skin cancer and highly chemoresistant. Melittin, an amphiphilic peptide containing 26 amino acid residues, is the major active ingredient from bee venom (BV). Although melittin is known to have several biological activities such as anti-inflammatory, antibacterial and anticancer effects, its antimelanoma effect and underlying molecular mechanism have not been fully elucidated. In the current study, we investigated the inhibitory effect and action mechanism of BV and melittin against various melanoma cells including B16F10, A375SM and SK-MEL-28. BV and melittin potently suppressed the growth, clonogenic survival, migration and invasion of melanoma cells. They also reduced the melanin formation in α-melanocyte-stimulating hormone (MSH)-stimulated melanoma cells. Furthermore, BV and melittin induced the apoptosis of melanoma cells by enhancing the activities of caspase-3 and -9. In addition, we demonstrated that the antimelanoma effect of BV and melittin is associated with the downregulation of PI3K/AKT/mTOR and MAPK signaling pathways. We also found that the combination of melittin with the chemotherapeutic agent temozolomide (TMZ) significantly increases the inhibition of growth as well as invasion in melanoma cells compared to melittin or TMZ alone. Taken together, these results suggest that melittin could be potentially applied for the prevention and treatment of malignant melanoma.
Keywords: AKT; MAPK; bee venom; melanoma; melittin; temozolomide.
Conflict of interest statement
The authors declare no conflict of interest.
Figures









Similar articles
-
Melittin suppresses EGF-induced cell motility and invasion by inhibiting PI3K/Akt/mTOR signaling pathway in breast cancer cells.Food Chem Toxicol. 2014 Jun;68:218-25. doi: 10.1016/j.fct.2014.03.022. Epub 2014 Mar 25. Food Chem Toxicol. 2014. PMID: 24675423
-
Bee venom and melittin reduce proinflammatory mediators in lipopolysaccharide-stimulated BV2 microglia.Int Immunopharmacol. 2007 Aug;7(8):1092-101. doi: 10.1016/j.intimp.2007.04.005. Epub 2007 May 2. Int Immunopharmacol. 2007. PMID: 17570326
-
Bee Venom and Its Major Component Melittin Attenuated Cutibacterium acnes- and IGF-1-Induced Acne Vulgaris via Inactivation of Akt/mTOR/SREBP Signaling Pathway.Int J Mol Sci. 2022 Mar 15;23(6):3152. doi: 10.3390/ijms23063152. Int J Mol Sci. 2022. PMID: 35328573 Free PMC article.
-
Bee Venom Components as Therapeutic Tools against Prostate Cancer.Toxins (Basel). 2021 May 7;13(5):337. doi: 10.3390/toxins13050337. Toxins (Basel). 2021. PMID: 34067049 Free PMC article. Review.
-
Anti-Inflammatory Applications of Melittin, a Major Component of Bee Venom: Detailed Mechanism of Action and Adverse Effects.Molecules. 2016 May 11;21(5):616. doi: 10.3390/molecules21050616. Molecules. 2016. PMID: 27187328 Free PMC article. Review.
Cited by
-
Key Genes Are Associated with the Prognosis of Glioma, and Melittin Can Regulate the Expression of These Genes in Glioma U87 Cells.Biomed Res Int. 2022 Dec 31;2022:7033478. doi: 10.1155/2022/7033478. eCollection 2022. Biomed Res Int. 2022. PMID: 39281062 Free PMC article.
-
Can Bee Venom Be Used as Anticancer Agent in Modern Medicine?Cancers (Basel). 2023 Jul 21;15(14):3714. doi: 10.3390/cancers15143714. Cancers (Basel). 2023. PMID: 37509375 Free PMC article. Review.
-
Pharmacological effects and mechanisms of bee venom and its main components: Recent progress and perspective.Front Pharmacol. 2022 Sep 27;13:1001553. doi: 10.3389/fphar.2022.1001553. eCollection 2022. Front Pharmacol. 2022. PMID: 36238572 Free PMC article. Review.
-
Melittin-Based Nanoparticles for Cancer Therapy: Mechanisms, Applications, and Future Perspectives.Pharmaceutics. 2025 Aug 6;17(8):1019. doi: 10.3390/pharmaceutics17081019. Pharmaceutics. 2025. PMID: 40871040 Free PMC article. Review.
-
Strategies for Improving Transdermal Administration: New Approaches to Controlled Drug Release.Pharmaceutics. 2023 Apr 7;15(4):1183. doi: 10.3390/pharmaceutics15041183. Pharmaceutics. 2023. PMID: 37111667 Free PMC article. Review.
References
-
- Kato M., Liu W., Akhand A.A., Hossain K., Takeda K., Takahashi M., Nakashima I. Ultraviolet radiation induces both full activation of ret kinase and malignant melanocytic tumor promotion in RFP-RET-transgenic mice. J. Investig. Dermatol. 2000;115:1157–1158. doi: 10.1046/j.1523-1747.2000.0202a-2.x. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous